Showing 1 - 6 results of 6 for search 'Zhongjun Xia', query time: 0.01s Refine Results
  1. 1
    Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma

    Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma by Demei Feng, Zhimin Yan, Bibo Fu, Shenrui Bai, Lewei Zhu, Robert Peter Gale, Zhongjun Xia, Yang Liang, Hua Wang

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Oxidative Stress Score as a Simplified Surrogate for Prognostic Stratification and Therapeutic Decision-Making in Multiple Myeloma

    Oxidative Stress Score as a Simplified Surrogate for Prognostic Stratification and Therapeutic Decision-Making in Multiple Myeloma by Qi Liang, Limei Zhang, Qianqian Huang, Weiran Lv, Zhijian Liang, Shutong Liu, Runcong Nie, Zhongjun Xia, Yang Liang, Yun Wang

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study

    Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospecti... by Mengqiu Wu, Peng Sun, Baitian Zhao, Hang Yang, Yi Xia, Man Nie, Qingqing Cai, Huiqiang Huang, He Huang, Zhongjun Xia, Yu Wang, Zhiming Li, Panpan Liu

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study

    Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study by Dong Liang, Yurong Yan, Shenrui Bai, Weiling Xu, Qiaoli Wang, Demei Feng, Yuying Bu, Min Zeng, Xiaomiao Nie, Yuan Feng, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Fengyan Jin, Hua Wang

    Published 2025-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

    Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer by Qian Zhou, Jinxia Liang, Tong Yang, Jin Liu, Bo Li, Yingchang Li, Zhenzhen Fan, Weida Wang, Wensheng Chen, Sujing Yuan, Meng Xu, Qigui Xu, Zhidong Luan, Zhongjun Xia, Penghui Zhou, Yadong Huang, Liang Chen

    Published 2021-12-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

    Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases by Zhi Guo, Zhi Guo, Jie Zhu, Jun Wang, Liang Wang, Feifei Tang, Huiqiang Huang, Zhongjun Xia, Liqiong Liu, Danyu Wang, Nan Zhong, Huanhuan Zhou, Zhaogui Zhou, Wei Dai, Xiaojun Xu, Hao Zhou, Lijuan Deng, Jingye Meng, Zhiqiang Sun, Liang Shao, Yu J. Cao, Yansong Liu, Rong Qu, Guowei Li, Peng Chen, Hongyan Zhang, Jing Liang, Yuhua Li, Yuhua Li, Jiajun Liu, Zishan Xu, Soong Sung Inda, Xiaochen Xiang, Qingming Wu, Qiang Wang

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: